Differential effects of classical neuroleptics and a newer generation antipsychotics on the MK-801 induced behavioural primitivization in mouse

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 30, Issue 3, 2006, Pages 521-530

  Nilsson, Marie ^a   Markinhuhta, Katarina Rydén ^b   Carlsson, Maria L ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b Carlsson Research AB   (Sweden)

Author keywords

Cognition; Mice; MK 801; Schizophrenia; Video tracking

Indexed keywords

6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; AMPA RECEPTOR AGONIST; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; DIZOCILPINE; NEUROLEPTIC AGENT; OLANZAPINE; SEROTONIN 2A ANTAGONIST; TRIFLUOPERAZINE; ZIPRASIDONE;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; COGNITION; CONTROLLED STUDY; DRUG EFFECT; HYPERACTIVITY; LOCOMOTION; MALE; MOUSE; MOVEMENT (PHYSIOLOGY); NONHUMAN; REARING;

ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; COGNITION; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; EXCITATORY AMINO ACID ANTAGONISTS; MALE; MICE; MOVEMENT DISORDERS; MULTIVARIATE ANALYSIS; STATISTICS, NONPARAMETRIC;

EID: 33646024620     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2005.11.010     Document Type: Article

References (46)

1. Abdul-Monim Z., Reynolds G.P., and Neill J.C. The atypical antipsychotic ziprasidone, but not haloperidol, improves phencyclidine-induced cognitive deficits in a reversal learning task in the rat. J Psychopharmacol 17 (2003) 57-65
2. Cannon M., Caspi A., Moffitt T.E., Harrington H., Taylor A., Murray R.M., et al. Evidence for early-childhood, pan-developmental impairment specific to schizophreniform disorder: results from a longitudinal birth cohort. Arch Gen Psychiatry 59 (2002) 449-456
3. Catafau A.M., Parellada E., Lomena F.J., Bernardo M., Pavia J., Ros D., et al. Prefrontal and temporal blood flow in schizophrenia: resting and activation technetium-99 m-HMPAO SPECT patterns in young neuroleptic-naive patients with acute disease. J Nucl Med 35 (1994) 935-941
4. Cornblatt B.A., and Keilp J.G. Impaired attention, genetics, and the pathophysiology of schizophrenia. Schizophr Bull 20 (1994) 31-46
5. Cuesta M.J., Peralta V., and Zarzuela A. Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study. Schizophr Res 48 (2001) 17-28
6. Cuzick J. A Wilcoxon-type test for trend. Stat Med 4 (1985) 87-90
7. Gobert A., Rivet J.M., Audinot V., Newman-Tancredi A., Cistarelli L., and Millan M.J. Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto- and heteroreceptor-mediated control of release. Neuroscience 84 (1998) 413-429
8. Goff D.C., Leahy L., Berman I., Posever T., Herz L., Leon A.C., et al. A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J Clin Psychopharmacol 21 (2001) 484-487
9. Goldberg T.E., Ragland J.D., Torrey E.F., Gold J.M., Bigelow L.B., and Weinberger D.R. Neuropsychological assessment of monozygotic twins discordant for schizophrenia. Arch Gen Psychiatry 47 (1990) 1066-1072
10. Goldman-Rakic P.S., and Selemon L.D. Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schizophr Bull 23 (1997) 437-458
11. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am J Psychiatry 153 (1996) 321-330
12. Hampson R.E., Rogers G., Lynch G., and Deadwyler S.A. Facilitative effects of the ampakine CX516 on short-term memory in rats: enhancement of delayed-nonmatch-to-sample performance. J Neurosci 18 (1998) 2740-2747
13. Hauber W. Clozapine improves dizocilpine-induced delayed alteration impairment in rats. J Neural Transm Gen Sect 94 (1993) 223-233
14. Healy D.J., and Meador-Woodruff J.H. Clozapine and haloperidol differentially affect AMPA and kainate receptor subunit mRNA levels in rat cortex and striatum. Brain Res Mol Brain Res 47 (1997) 331-338
15. Hoff A.L., Riordan H., O'Donnell D.W., Morris L., and DeLisi L.E. Neuropsychological functioning of first-episode schizophreniform patients. Am J Psychiatry 149 (1992) 898-903
16. Ingvar M., Ambros-Ingerson J., Davis M., Granger R., Kessler M., Rogers G.A., et al. Enhancement by an ampakine of memory encoding in humans. Exp Neurol 146 (1997) 553-559
17. Jackson J.E. A user's guide to principal components a wiley-interscience publication (1991), John Wiley and Sons, Inc., New York
18. Jaeger J., and Douglas E. Neuropsychiatric rehabilitation for persistent mental illness. Psychiatr Q 63 (1992) 71-94
19. Keefe R.S., Silva S.G., Perkins D.O., and Lieberman J.A. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 25 (1999) 201-222
20. Krausz M., Moritz S., Lambert M., and Naber D. Dosage of conventional neuroleptic medication and subjective cognitive functioning in schizophrenia. Int Clin Psychopharmacol 15 (2000) 77-81
21. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses, arch gen psychiatry vol. 51 (1994) 199-214
22. Kuroki T., Meltzer H.Y., and Ichikawa J. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther 288 (1999) 774-781
23. Lahti A.C., Koffel B., LaPorte D., and Tamminga C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13 (1995) 9-19
24. Malhotra A.K., Pinals D.A., Weingartner H., Sirocco K., Missar C.D., Pickar D., et al. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 14 (1996) 301-307
25. Marenco S., Egan M.F., Goldberg T.E., Knable M.B., McClure R.K., Winterer G., et al. Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: a case series. Schizophr Res 57 (2002) 221-226
26. Medalia A., Gold J., and Merriam A. The effects of neuroleptics on neuropsychological test results of schizophrenics. Arch Clin Neuropsychol 3 (1988) 249-271
27. Meltzer H.Y., and McGurk S.R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25 (1999) 233-255
28. Nilsson M., Waters S., Waters N., Carlsson A., and Carlsson M.L. A behavioural pattern analysis of hypoglutamatergic mice-effects of four different antipsychotic agents. J Neural Transm 108 (2001) 1181-1196
29. Ninan I., and Kulkarni S.K. Effect of olanzapine on behavioural changes induced by FG 7142 and dizocilpine on active avoidance and plus maze tasks. Brain Res 830 (1999) 337-344
30. Ogawa S., Okuyama S., Araki H., and Otomo S. Effect of NE-100, a novel sigma receptor ligand, on phencyclidine-induced cognitive dysfunction. Eur J Pharmacol 263 (1994) 9-15
31. Okuyama S., Chaki S., Kawashima N., Suzuki Y., Ogawa S., Kumagai T., et al. The atypical antipsychotic profile of NRA0045, a novel dopamine D4 and 5-hydroxytryptamine 2A receptor antagonist, in rats. Br J Pharmacol 121 (1997) 515-525
32. Riva M.A., Tascedda F., Lovati E., and Racagni G. Regulation of NMDA receptor subunit messenger RNA levels in the rat brain following acute and chronic exposure to antipsychotic drugs. Brain Res Mol Brain Res 50 (1997) 136-142
33. Rollema H., Lu Y., Schmidt A.W., Sprouse J.S., and Zorn S.H. 5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol Psychiatry 48 (2000) 229-237
34. Rubin P., Holm S., Friberg L., Videbech P., Andersen H.S., Bendsen B.B., et al. Altered modulation of prefrontal and subcortical brain activity in newly diagnosed schizophrenia and schizophreniform disorder. A regional cerebral blood flow study. Arch Gen Psychiatry 48 (1991) 987-995
35. Saykin A.J., Shtasel D.L., Gur R.E., Kester D.B., Mozley L.H., Stafiniak P., et al. Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch Gen Psychiatry 51 (1994) 124-131
36. Sharma T. Cognitive effects of conventional and atypical antipsychotics in schizophrenia. Br J Psychiatr Suppl 38 (1999) 44-51
37. Sjöström M., Wold S., and Söderström B. PLS discriminant plots. In: Gelesema E.S., and Kanal L.N. (Eds). Pattern recognition in practice vol. II (1986), Elsevier Science Publicher BV, North Holland 461-470
38. Stone M. Cross-validatory choice and assessment of statistical predictions. J R Stat Soc B36 (1974) 111-147
39. Tascedda F., Lovati E., Blom J.M., Muzzioli P., Brunello N., Racagni G., et al. Regulation of ionotropic glutamate receptors in the rat brain in response to the atypical antipsychotic seroquel (quetiapine fumarate). Neuropsychopharmacology 21 (1999) 211-217
40. Tascedda F., Blom J.M., Brunello N., Zolin K., Gennarelli M., Colzi A., et al. Modulation of glutamate receptors in response to the novel antipsychotic olanzapine in rats. Biol Psychiatry 50 (2001) 117-122
41. Tsai G., Yang P., Chung L.C., Lange N., and Coyle J.T. d-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 44 (1998) 1081-1089
42. Volz H.P., Gaser C., Hager F., Rzanny R., Mentzel H.J., Kreitschmann-Andermahr I., et al. Brain activation during cognitive stimulation with the Wisconsin Card Sorting Test-a functional MRI study on healthy volunteers and schizophrenics. Psychiatry Res 75 (1997) 145-157
43. Wold S. Cross-validatory estimation of the number of components in factor and principal components models. Technometrics 20 (1978) 397-405
44. Wold S., Albano C., Dunn W.J., Edlund U., Esbensen K., Geladi P., et al. Multivariate data analysis in chemistry. In: Kowalski B.R. (Ed). Chemometrics: mathematics and statistics in chemistry (1984), D. Reidel publishing company, Dordrecht, Holland
45. Wold S., Sjöström M., and Eriksson L. Partial least squares projections to latent structures (PLS) in Chemistry. In: Schleyer P.V., Allinger N.L., Clark T., Gasteiger J., Kollman P.A., Schaefer H.F., and Schreiner P.R. (Eds). The encyclopedia of computational chemistry (1999), John Wiley and Sons, Chichester 2006-2020
46. Wood P.L. The co-agonist concept: is the NMDA-associated glycine receptor saturated in vivo?. Life Sci 57 (1995) 301-310